Kenvue (NYSE:KVUE) Announces Earnings Results, Beats Estimates By $0.01 EPS

Kenvue (NYSE:KVUE) posted its quarterly earnings data on Monday. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01, Zacks reports. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. During the same period last year, the firm posted $0.28 EPS. Kenvue’s quarterly revenue was down 3.5% on a year-over-year basis. Kenvue updated its FY 2025 guidance to 1.000-1.050 EPS.

Kenvue Price Performance

Kenvue stock opened at $16.18 on Tuesday. Kenvue has a one year low of $14.02 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The business has a fifty day moving average of $17.11 and a two-hundred day moving average of $20.45. The company has a market cap of $31.06 billion, a P/E ratio of 21.87, a price-to-earnings-growth ratio of 2.07 and a beta of 0.71.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be issued a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 5.1%. Kenvue’s dividend payout ratio (DPR) is 112.16%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a research report on Monday, August 11th. Finally, Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $22.50 to $22.00 in a research report on Friday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.17.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Alliancebernstein L.P. boosted its position in shares of Kenvue by 115.9% in the 2nd quarter. Alliancebernstein L.P. now owns 6,438,473 shares of the company’s stock worth $134,757,000 after buying an additional 3,456,204 shares in the last quarter. Scopus Asset Management L.P. purchased a new stake in shares of Kenvue in the 2nd quarter worth about $40,394,000. Canada Pension Plan Investment Board boosted its position in shares of Kenvue by 164.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 2,694,498 shares of the company’s stock worth $56,396,000 after buying an additional 1,674,072 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Kenvue in the 2nd quarter worth about $22,897,000. Finally, Man Group plc boosted its position in shares of Kenvue by 1,815.8% in the 2nd quarter. Man Group plc now owns 855,280 shares of the company’s stock worth $17,901,000 after buying an additional 810,636 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.